Literature DB >> 31955003

Micropapillary pattern is associated with the development of brain metastases and the reduction of survival time in EGFR-mutation lung adenocarcinoma patients with surgery.

Changhui Li1, Yinchen Shen1, Fang Hu1, Tianqing Chu1, Xiaohua Yang2, Jinchen Shao3, Xiaoxuan Zheng1, Jianlin Xu1, Hai Zhang1, Baohui Han1, Hua Zhong4, Xueyan Zhang5.   

Abstract

OBJECTIVE: The role of micropapillary pattern (MIP) in EGFR-mutated NSCLC patients with brain metastases (BM) after complete surgical resection still remains unclear. Therefore, a retrospective study was conducted to evaluate the role of MIP in those patients.
METHODS: This study included 332 stage I-III patients with EGFR-mutant lung adenocarcinoma and complete resection. Patients were classified in four groups: the MIP-positive patients without BM development, the MIP-negative patients without BM development, the MIP-positive patients with BM development and the MIP-negative patients with BM development. Intracranial disease-free survival (iDFS), systemic disease-free survival (DFS) and overall survival (OS) were evaluated.
RESULTS: The median OS in the whole group was 70 months. The patients with MIP show inferior DFS (13 months vs. 22 months; P < 0.001) and OS (56 months vs. 74 months; P < 0.001). Furthermore, BM development was more likely to be found in patients with MIP (P = 0.001). In addition, the MIP-positive patients showed a significantly shorter iDFS compared with MIP-negative patients (14.5 months vs. 26 months; P < 0.001). Furthermore, the MIP-positive patients had significantly inferior iDFS in both BM as first line development groups (13 months vs. 19 months; P < 0.001) and BM as non-first line development groups (18 months vs. 33 months; P = 0.007).
CONCLUSIONS: MIP was related to the earlier recurrence and shortened survival time. In addition, MIP was an independent poor prognostic factor for the increase of BM rate and the shortened time of BM development after surgery.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Brain metastases; EGFR; Lung adenocarcinoma; Micropapillary; Surgical resection

Mesh:

Substances:

Year:  2020        PMID: 31955003     DOI: 10.1016/j.lungcan.2020.01.007

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  7 in total

1.  Personalized post-surgical care?-possible strategies for NSCLCs with EGFR mutation.

Authors:  Kenichi Suda
Journal:  Transl Lung Cancer Res       Date:  2020-06

2.  High-risk-pattern lung adenocarcinoma with epidermal growth factor receptor mutation is associated with distant metastasis risk and may benefit from adjuvant targeted therapy.

Authors:  Liang Wang; Xing Wang; Miao Huang; Shi Yan; Shaolei Li; Chao Lv; Nan Wu; Yue Yang
Journal:  Interact Cardiovasc Thorac Surg       Date:  2021-08-18

3.  Combination of epidermal growth factor receptor mutation and the presence of high-grade patterns is associated with recurrence in resected stage I lung adenocarcinoma.

Authors:  Yasuto Kondo; Junji Ichinose; Hironori Ninomiya; Kohei Hashimoto; Yosuke Matsuura; Masayuki Nakao; Yuichi Ishikawa; Sakae Okumura; Yukitoshi Satoh; Mingyon Mun
Journal:  Interact Cardiovasc Thorac Surg       Date:  2022-07-09

4.  A Nomogram for Predicting Brain Metastasis in IIIA-N2 Non-Small Cell Lung Cancer After Complete Resection: A Competing Risk Analysis.

Authors:  Shuang Sun; Yu Men; Jingjing Kang; Xin Sun; Meng Yuan; Xu Yang; Yongxing Bao; Jianyang Wang; Lei Deng; Wenqing Wang; Yirui Zhai; Wenyang Liu; Tao Zhang; Xin Wang; Nan Bi; Jima Lv; Jun Liang; Qinfu Feng; Dongfu Chen; Zefen Xiao; Zongmei Zhou; Luhua Wang; Zhouguang Hui
Journal:  Front Oncol       Date:  2021-12-13       Impact factor: 6.244

5.  Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors as a first-line treatment for postoperative recurrent and EGFR-mutated non-small-cell lung cancer.

Authors:  Tetsuji Moriya; Masatsugu Hamaji; Akihiko Yoshizawa; Ryo Miyata; Misa Noguchi; Shigeyuki Tamari; Naohisa Chiba; Hideaki Miyamoto; Toshiya Toyazaki; Satona Tanaka; Yoshito Yamada; Yojiro Yutaka; Daisuke Nakajima; Akihiro Ohsumi; Toshi Menju; Hiroshi Date
Journal:  Interact Cardiovasc Thorac Surg       Date:  2022-02-21

Review 6.  [Research Progress on Risk Factors of Brain Metastasis in Non-small Cell Lung Cancer].

Authors:  Shuang Sun; Yu Men; Zhouguang Hui
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2022-03-20

7.  Sphingomyelin(d35:1) as a novel predictor for lung adenocarcinoma recurrence after a radical surgery: a case-control study.

Authors:  Yusuke Takanashi; Kazuhito Funai; Shumpei Sato; Akikazu Kawase; Hong Tao; Yutaka Takahashi; Haruhiko Sugimura; Mitsutoshi Setou; Tomoaki Kahyo; Norihiko Shiiya
Journal:  BMC Cancer       Date:  2020-08-24       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.